Aditxt, Inc. (ADTX)
NASDAQ: ADTX · IEX Real-Time Price · USD
1.350
-0.030 (-2.17%)
At close: Jul 26, 2024, 4:00 PM
1.390
+0.040 (2.96%)
After-hours: Jul 26, 2024, 7:24 PM EDT
Aditxt Revenue
Aditxt had revenue of $79.68K in the quarter ending March 31, 2024, a decrease of -63.52%. This brings the company's revenue in the last twelve months to $506.44K, down -46.23% year-over-year. In the year 2023, Aditxt had annual revenue of $645.18K, down -30.90%.
Revenue (ttm)
$506.44K
Revenue Growth
-46.23%
P/S Ratio
5.31
Revenue / Employee
$10,775
Employees
47
Market Cap
2.69M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Xylo Technologies | 91.72M |
NovaBay Pharmaceuticals | 14.23M |
Petros Pharmaceuticals | 4.69M |
INVO Bioscience | 4.25M |
Qualigen Therapeutics | 1.63M |
ADTX News
- 1 day ago - Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st - GlobeNewsWire
- 1 day ago - Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition - Business Wire
- 3 days ago - Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1 - PRNewsWire
- 9 days ago - Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing - Business Wire
- 11 days ago - Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC - PRNewsWire
- 4 weeks ago - Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare - PRNewsWire
- 6 weeks ago - Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter - PRNewsWire
- 2 months ago - Evofem Biosciences Announces Financial Results for the First Quarter of 2024 - PRNewsWire